A strong trading performance sees the company expecting to report 2015 revenues of £43.2m vs PGe £42.9m (2014: £42.0m), up 3% in spite of Euro weakness, reflecting underlying revenue growth of 11% (£46.6m constant currency). Outperformance against flat market growth is translating to market share gains of c.1% p.a. and, alongside M&A (most recently with Alerpharma S.A.) and the funded US pipeline programme (Pollinex Quattro), we consider there are strong long-term
